<PAGE>   1

================================================================================

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                  FORM 10-KSB/A
(Mark One)

   [X]            ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                   For the fiscal year ended December 31, 2000
                                       OR
   [ ]         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
               For the transition period from _______ to ________

                         Commission file number 0-20532

                            DEXTERITY SURGICAL, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                       DELAWARE                                74-2559866
           (STATE OR OTHER JURISDICTION OF                  (I.R.S. EMPLOYER
            INCORPORATION OR ORGANIZATION)                 IDENTIFICATION NO.)

          12961 PARK CENTRAL, SUITE 1300
                 SAN ANTONIO, TEXAS                              78216
     (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)                  (ZIP CODE)

      REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (210) 495-8787

                                   ----------

        SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE

           SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

                          Common Stock, $.001 par value
                                (TITLE OF CLASS)

         INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS
REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS.  YES  X   NO    .
                                               ---     ---

         INDICATE BY CHECK MARK IF DISCLOSURE OF DELINQUENT FILERS PURSUANT TO
ITEM 405 OF REGULATION S-B IS NOT CONTAINED HEREIN, AND WILL NOT BE CONTAINED,
TO THE BEST OF REGISTRANT'S KNOWLEDGE, IN DEFINITIVE PROXY OR INFORMATION
STATEMENTS INCORPORATED BY REFERENCE IN PART III OF THIS FORM 10-KSB OR ANY
AMENDMENT TO THIS FORM 10-KSB  X
                              ---

         REGISTRANT'S REVENUES FOR FISCAL YEAR ENDED DECEMBER 31,2000:
$6,587,000.

         AT MARCH 15, 2001 (BASED UPON THE LAST REPORTED SALES PRICE OF $.125
PER SHARE), THE AGGREGATE MARKET VALUE OF THE COMMON STOCK, $.001 PAR VALUE, OF
THE REGISTRANT HELD BY NON-AFFILIATES WAS APPROXIMATELY $1,024,895. AT MARCH 15,
2001, THERE WERE OUTSTANDING 11,521,492 SHARES OF COMMON STOCK, $.001 PAR VALUE,
OF THE REGISTRANT.


                       DOCUMENTS INCORPORATED BY REFERENCE


    DOCUMENT                                    FORM 10-KSB PART
    --------                                    ----------------
Definitive Proxy Statement for 2001 Annual      Part III, Items 9, 10 11 and 12
  Meeting of Stockholders

Transitional Small Business Disclosure Format.  Yes     No  X .
                                                   ---     ---
================================================================================
<PAGE>   2
ITEM 3.                        LEGAL PROCEEDINGS

         The Company filed a lawsuit for breach of contract on September 11,
2000 in the Superior Court of the State of California, City and County of San
Francisco, against General Surgical Innovations, Inc. and United Slates Surgical
Corporation. The lawsuit relates to the unilateral termination of the Company's
distribution agreement with GSI.

         The Company had a $359,940.80 judgment entered against it in February
2001 as a result of a lawsuit filed against it in Georgia state court alleging
breach of contract. The Company has filed a motion for a new trial and, in the
event the motion is denied, the Company intends to appeal the judgment. The
Company believes it has meritorious defenses to the lawsuit and intends to
vigorously defend itself. In the event of an unfavorable outcome, the Company
believes that it is entitled to indemnification from the former shareholders of
Val-U-Med, Inc. for 42 to 100% of any ultimate judgment.

         The Company is a party to claims and legal proceedings arising in the
ordinary course of business. The Company believes it is unlikely that the final
outcome of any of the claims or proceedings to which the Company is a party,
including the case described above, would have a material adverse effect on the
Company's financial statements; however, due to the inherent uncertainty of
litigation, the range of possible loss, if any, cannot be estimated with a
reasonable degree of precision and there can be no assurance that the resolution
of any particular claim or proceeding would not have an adverse effect on the
Company's results of operations for the interim period in which such resolution
occurred.




<PAGE>   3
                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                        DEXTERITY SURGICAL, INC.


April 6, 2001                           By  /s/ Richard A. Woodfield
                                          -------------------------------------
                                                  Richard A. Woodfield
                                          President and Chief Executive Officer


         Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

<TABLE>
<CAPTION>


SIGNATURE                                         TITLE                              DATE
---------                                         -----                              ----
<S>                                   <C>                                       <C>
/s/ Richard A. Woodfield              President, Chief Executive Officer        April 6, 2001
--------------------------            and Director (Principal Executive
Richard A. Woodfield                  Officer)

/s/ Randall K. Boatright              Executive Vice President, Chief           April 6, 2001
--------------------------            Financial Officer and Director
Randall K. Boatright                  (Principal Financial and
                                      Accounting Officer)

/s/ Jeffrey H. Berg, Ph.D.            Director                                  April 6, 2001
--------------------------
Jeffrey H. Berg, Ph.D.


                                      Director
--------------------------
Robert L. Evans


/s/ William H. Bookwalter             Director                                  April 6, 2001
--------------------------
William H. Bookwalter


/s/ Christopher K. Black              Director                                  April 6, 2001
--------------------------
Christopher K. Black
</TABLE>



                                      S-1



<PAGE>   4
                                 EXHIBIT INDEX

<TABLE>
EXHIBIT
NUMBER            DESCRIPTION
-------           -----------
<S>               <C>
  23.1            Consent of Ernst & Young LLP
</TABLE>